SME Phase 2 winner- Tarsius Pharma

ISERD congratulates Tarsius Pharma!

Tarsius Pharma has been selected for funding in the SME Instrument Phase 2 EU grant, for the treatment of blindness-causing ocular diseases. The SME Instrument\EIC Accelerator scheme is granted for innovative, groundbreaking and disruptive technologies.

Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of million people worldwide and posing severe risks of vision loss and blindness. TRS, the Tarsius bio-inspired technology, approaches inflammatory diseases from within the immune system. Tarsius Pharma implements a patented, proprietary new molecule which was developed to 're-engineer' the immune system.

See publication here.